Business
The Jenex Corporation Announces Graduation to the TSX Venture, Update on Chinese Global Financial Forum and Proposed Acquisition
Toronto, Ontario--(Newsfile Corp. - December 12, 2017) - The Jenex Corporation (NEX: JEN.H) (T...
About this update from Therma Bright Inc.
[{"type":"text","content":"The Jenex Corporation Announces Graduation to the TSX Venture, Update on Chinese Global Financial Forum and Proposed AcquisitionToronto, Ontario--(Newsfile Corp. - December 12, 2017) - The Jenex Corporation (NEX: JEN.H) (TSXV: JEN) (\"Jenex\" or the \"Company\"), a progressive medical device technology company, today announces that the Company has met the requirements to be listed as a TSX Venture Tier 2 Company.  Effective December 13, 2017, the Company's listing will transfer from NEX to TSX Venture, the Company's Tier classification will change from NEX to Tier 2 and the filing and service office will change from NEX to Toronto. Effective at the opening, December 13, 2017, the trading symbol for the Company will change from JEN.H to JEN.On December 7th, 2017, Jenex presented its InterceptCS™ technology for cold sores and its TherOZap™ technology, currently being tested to inactivate the Zika virus, at the Chinese Global Financial Forum along with the proposed medical device target acquisitions for acne and other cosmetic applications. The conference took place in Shenzhen, China, a city with a population of 11.91M, which many consider the 'Silicon Valley' of China. Jenex presented to Chinese funds, enterprises and other large-scale investors that have focused on outbound investments, trade sales and licensing deals as their strategic focus. In addition, Jenex was interviewed by a local TV network. Immediately following the presentation Jenex was approached by several entities to fund, market, distribute and manufacture its products for the Chinese marketplace. As a result of the strong interest in Jenex's products and given the size and scope of China's consumer market and demand for cosmetic based medical device solutions, the Company believes its products are ideal to market and sell to the Chinese marketplace. Jenex will aggressively pursue market opportunities in China for its inventory of InterceptCS™ technology and near-term commercialization of the TherOZap™ technology, and proposed acquisition products in acne and other cosmetic applications. As previously reported on November 2nd, 2017, relating to the Proposed Acquisition for acne and other cosmetic applications, Jenex has agreed with the vendor of the Target Acquisitions to extend the execution of a definitive share p...